GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elekta AB (OTCPK:EKTAF) » Definitions » Institutional Ownership

Elekta AB (Elekta AB) Institutional Ownership : 55.65% (As of May. 18, 2024)


View and export this data going back to . Start your Free Trial

What is Elekta AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Elekta AB's institutional ownership is 55.65%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Elekta AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Elekta AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Elekta AB Institutional Ownership Historical Data

The historical data trend for Elekta AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elekta AB Institutional Ownership Chart

Elekta AB Historical Data

The historical data trend for Elekta AB can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 56.20 54.30 53.86 53.92 54.14 55.66 55.90 55.33 55.70 55.65

Elekta AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Elekta AB (Elekta AB) Business Description

Address
Kungstensgatan 18, Box 7593, Stockholm, SWE, SE-103 93
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company's installed base of more than 5,000 linear accelerators, GammaKnife and Unity platforms, and software is used in more than 6,000 hospitals globally. The company's sales are evenly distributed across geographies, with North and South America accounting for 31%; Europe, the Middle East, and Africa accounting for 35%; and Asia-Pacific contributing the remainder.